Here’s some interesting news for anyone living with ankylosing spondylitis (AS):
A growing prevalence in AS around the globe has translated into increased spending on—and development of—more reliable treatments.
Persistence Market Research (PMR) released a report last year, Ankylosing Spondylitis Treatment Market: Global Industry Analysis and Forecast 2015 – 2021. PMR looked at historical data and trends, and projected what the AS market will look like over the next few years.
The most startling statistic is a worldwide spike in AS prevalence, especially in China and India. But as AS awareness has grown, so has investment in new medications, treatment approaches, and devices.
Today’s treatments are more reliable and run the gamut from biologics like Humira and Embrel, to surgical procedures and occupational therapy. Government investment in healthcare infrastructure—especially in European countries—means that many of the world’s markets will be well-equipped to deal with all the current and upcoming AS cases.
But the big takeaway has to be that more awareness DOES make a difference. Getting the word out about the impact of a painful condition like AS means that the best driver of the market is what customers need and demand. That’s as true in medicine as it is in anything. So keep making noise!